SpyGlass Pharma, Inc. Common Stock (SGP)

SpyGlass Pharma, Inc. Common Stock (SGP) — VMCI valuation read

SGP screens at VMCI 28/100, a 23-point gap below the Healthcare sector median (50). For a mid-cap SpyGlass Pharma, Inc. Common Stock share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

SGP has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SGP trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.1x leaves covenant headroom, which sets the rate-cycle exposure for SpyGlass Pharma, Inc. Common Stock.

SGP rose 0.9% over the trailing 7 days, with a -23.6% read on a 30-day basis.